Skip to content
Sandu Pharmaceuticals logo

Sandu Pharmaceuticals

524703 BSE
₹36.00 down 0.83 (2.25%)
Market Cap
₹34.74 Cr
P/E
19.67

Sandu Pharmaceuticals (SANDUPHQ) share price was ₹36.83 at the 28 Oct 2026 close; market capitalisation ₹35.54 Cr; P/E (TTM) 20.13; sector Healthcare. The share price fell 15.3% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 1.9% year on year to ₹16.39 Cr and net profit was ₹0.23 Cr, against ₹0.22 Cr a year earlier (compared with Jun 2025). Promoters held 37.79% of Sandu Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 57/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹36.83 −7.14 −16.24% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹34.74 Cr
P/E (TTM)
19.67
EBITDA
₹2.90 Cr
Return on Equity
3.69%
Debt to Equity
0
Book Value
₹36.48
EPS (TTM)
₹1.83
52W High
₹50.00
52W Low
₹30.00

Price-based figures as of 29 Oct 2026, 10:26 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,763.6034.994,23,147 Cr5.060.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,664.0087.712,56,549 Cr15.310.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,588.3072.031,74,524 Cr9.500.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,195.10108.451,18,604 Cr22.380.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,183.9026.341,18,094 Cr4.360.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.7034.671,11,739 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.7032.721,10,329 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Sandu Pharmaceuticals (this company)
₹36.0019.6735 Cr0.992.89%3.69%5.18%67 Cr2 Cr
Median 8 companies₹1,564.6534.831,18,349 Cr4.710.72%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

57 Good
Overall score

Data confidence 98/100

Category scores

Quality Strong 66
Returns, margins, earnings quality 22% weight
Valuation Strong 69
Cheap vs sector & own history 24% weight
Growth Weak 43
Sales & profit trajectory 9% weight
Financial Health Good 60
Solvency, leverage, coverage 9% weight
Momentum Weak 40
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 0.82 times its book value
  • Company's working capital requirements have reduced from 53.8 days to 42.0 days

Weaknesses

4
  • The company has delivered a poor sales growth of 3.54% over past five years.
  • Promoter holding is low: 37.8%
  • Company has a low return on equity of 3.85% over last 3 years.
  • Promoter holding has decreased over last 3 years: -5.12%

Technical Indicators

Oscillators

Bullish

Bearish
2
Neutral
4
Bullish
3

Overall

Bullish

Bearish
6
Neutral
4
Bullish
9

Moving Averages

Bullish

Bearish
4
Neutral
0
Bullish
6

Growth Rate

Revenue Growth
-0.44% lower than 3Y

change over 1 year

Net Income Growth
6.67% higher than 3Y

change over 1 year

Cash Flow Change
25%

change over 1 year

EBITDA Margin Change
8.21%

change over 1 year Operating margin 3.23% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
17.66
16.61
17.43
15.6
17.05
17.7
18.37
14.07
16.7
17.62
18.76
16.85
16.39
Expenses
17.31
15.79
16.92
15
16.64
16.78
17.37
13.62
16.17
16.76
17.72
16.28
15.86
Operating Profit
0.35
0.82
0.51
0.6
0.41
0.92
1
0.45
0.53
0.86
1.04
0.57
0.53
OPM %
1.98%
4.94%
2.93%
3.85%
2.4%
5.2%
5.44%
3.2%
3.17%
4.88%
5.54%
3.38%
3.23%
Other Income
0
0.09
0.03
0.31
0.04
0.03
0.02
0.07
0.02
0.05
0.01
0.37
0.02
Interest
0.02
0.01
0.02
0.01
0.02
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
Depreciation
0.12
0.13
0.14
0.19
0.16
0.17
0.19
0.15
0.18
0.17
0.17
0.16
0.16
PBT
0.21
0.77
0.38
0.71
0.27
0.75
0.8
0.34
0.34
0.71
0.85
0.75
0.36
Tax %
47.62%
27.27%
44.74%
16.9%
40.74%
32%
30%
2.94%
35.29%
26.76%
-14.12%
93.33%
36.11%
Net Profit
0.11
0.55
0.21
0.59
0.17
0.5
0.56
0.33
0.22
0.52
0.98
0.04
0.23
EPS (₹)
0.11
0.57
0.22
0.61
0.18
0.52
0.58
0.34
0.23
0.54
1.01
0.04
0.24
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
38.17
38.86
42.82
49.02
49.42
48.37
58.76
65.5
65.35
67.28
67.19
69.93
69.62
Expenses
35.74
35.97
40.97
46.55
47.33
46.92
56.6
62.62
62.86
64.98
64.43
66.93
66.62
Operating Profit
2.43
2.89
1.85
2.47
2.09
1.45
2.16
2.88
2.49
2.3
2.76
3
3
OPM %
6.37%
7.44%
4.32%
5.04%
4.23%
3%
3.68%
4.4%
3.81%
3.42%
4.11%
4.29%
4.31%
Other Income
0.14
0.12
0.56
0.12
0.57
0.45
0.19
0.08
0.33
0.42
0.17
0.44
0.45
Interest
1.37
1.64
1.49
1.23
1.01
0.43
0.11
0.11
0.08
0.06
0.1
0.11
0.12
Depreciation
0.57
0.69
0.87
0.6
0.64
0.55
0.56
0.53
0.52
0.58
0.67
0.68
0.66
PBT
0.63
0.68
0.05
0.76
1.01
0.92
1.68
2.32
2.22
2.08
2.16
2.65
2.67
Tax %
34.92%
22.06%
1000%
26.32%
34.65%
21.74%
35.12%
31.47%
31.08%
29.33%
28.24%
33.58%
—
Net Profit
0.41
0.54
-0.44
0.56
0.67
0.72
1.09
1.59
1.52
1.46
1.55
1.77
1.77
EPS (₹)
0.58
0.76
-0.62
0.79
0.95
1.02
1.38
1.8
1.57
1.51
1.6
1.83
1.83
Div. Payout %
0%
0%
0%
0%
0%
0%
36.33%
41.56%
0%
52.93%
49.86%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7.08
7.08
7.08
7.08
7.08
7.08
7.92
8.81
9.66
9.66
9.66
9.66
Reserves
11.06
11.6
20.33
21
21.71
22.16
25.57
27.66
29.58
30.93
32.36
34.01
Borrowings
12.47
11.39
10.56
9.42
6.17
1.25
0.02
0
0
0
0.06
0.11
Other Liabilities
10.91
11.33
8.46
7.03
8.67
10.92
13.45
12.81
14.92
11.83
13.64
12.09
Total Liabilities
41.52
41.4
46.43
44.53
43.63
41.41
46.96
49.28
54.16
52.42
55.72
55.87
Fixed Assets
8.36
7.81
17.49
17.57
17.04
16.6
16.17
16
16.62
17.88
18.15
18.12
CWIP
0
0
0
0
0
0
0
0.48
0.42
0
0
0.06
Investments
0.7
0.73
0.99
1.12
1.13
0.82
0.24
9.11
9.66
10.43
11.22
12.3
Other Assets
32.46
32.86
27.95
25.84
25.46
23.99
30.55
23.69
27.46
24.11
26.35
25.39
Total Assets
41.52
41.4
46.43
44.53
43.63
41.41
46.96
49.28
54.16
52.42
55.72
55.87
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4.75
-1.43
4.91
1.23
3.74
6.2
7.59
0.95
0.22
0.76
0.95
6.12
Investing
-0.18
0.05
-0.59
-0.62
-0.1
-0.37
-5.58
-5.47
0.53
-1.31
-0.18
-0.57
Financing
-1.9
-2.06
-2.33
-1.89
-4.26
-5.36
1.3
0.93
0.58
-0.72
-0.46
-0.94
Net Cash Flow
2.67
-3.44
1.99
-1.28
-0.62
0.48
3.31
-3.59
1.33
-1.27
0.31
4.6
Free Cash Flow
4.43
-1.58
4.3
0.6
3.63
6.09
7.46
0.11
-0.85
-0.67
0.01
5.4
CFO/OP
201
-42
195
63
194
437
373
64
37
55
55
229
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
62.73
67.16
54.13
49.81
35.45
35.32
33.23
22.23
26.75
26.42
25.86
28.24
Inventory Days
210
207
152
147
191
209
118
115
168
137
161
121
Days Payable
103
101
58.22
38.75
60.93
83.69
70.57
69.63
98.3
46.96
51.05
51.68
Cash Conversion Cycle
169
173
148
158
166
160
80.52
67.67
96.15
117
136
97.61
Working Capital Days
68.47
105
60.69
30.16
40.1
72.06
39.51
42.41
52.33
56.75
62.8
41.96
ROCE %
6.8%
7.75%
4.26%
5.14%
5.58%
4.13%
5.59%
6.94%
6.08%
5.36%
5.47%
6.43%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sandu Pharmaceuticals insights

66 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

DIIs0.02%Promot.37.79%Others25.12%Public37.08%As ofSep 2026

Documents

Frequently Asked Questions about Sandu Pharmaceuticals

What does Sandu Pharmaceuticals Ltd do?
Incorporated in 1985, Sandu Pharmaceuticals Ltd is a manufacturer of Ayurvedic Medicines.[1]
Where is Sandu Pharmaceuticals Ltd (SANDUPHQ) listed?
Sandu Pharmaceuticals Ltd trades under code 524703 on the BSE.
Which sector does Sandu Pharmaceuticals Ltd belong to?
Sandu Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Sandu Pharmaceuticals Ltd?
Sandu Pharmaceuticals Ltd has a market capitalisation of ₹34.74 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Sandu Pharmaceuticals Ltd?
Sandu Pharmaceuticals Ltd trades at a PE ratio of 19.67 as of 29 Oct 2026, on earnings per share of ₹1.83, against a book value of ₹36.48 per share.
What is the 52-week high and low of Sandu Pharmaceuticals Ltd?
Over the last 52 weeks Sandu Pharmaceuticals Ltd has traded between ₹30 and ₹50 as of 29 Oct 2026.
Does Sandu Pharmaceuticals Ltd pay dividends?
Sandu Pharmaceuticals Ltd has a dividend yield of 2.72%.
What is the Return on Equity (ROE) of Sandu Pharmaceuticals Ltd?
Sandu Pharmaceuticals Ltd reported a return on equity of 3.69%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1985, Sandu Pharmaceuticals Ltd is a manufacturer of Ayurvedic Medicines.[1]

Website sandu.in
Face Value ₹ 10
Shares Outstanding 96,49,377

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524703.md for Sandu Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month